Saudi Arabia Sets Sights On Becoming Global Biotech Leader With National Strategy

The Chief Executive Officer of the Saudi Food and Drug Authority (SFDA), Dr. Hisham bin Saad Al-Jadhey, has affirmed that Saudi Arabia’s National Biotechnology Strategy is set to position the Kingdom as a global leader in biomanufacturing and medical innovation. This strategy prioritises critical areas such as vaccines, biolocalisation, genomics, and plant improvement.

Speaking at the fourth annual international conference of the Saudi Society of Clinical Pharmacy (SSCP), Dr. Al-Jadhey highlighted the SFDA’s pivotal role in implementing this strategy. He emphasised the Authority’s efforts in creating a robust regulatory framework for biotechnology, which includes establishing clinical trial protocols for biopharmaceuticals, setting manufacturing standards for bioproducts, overseeing clinical evaluations, and monitoring the safety of bioproducts post-market.

Dr. Al-Jadhey also stressed that the Kingdom’s health system views biotechnology holistically. The focus is on enhancing quality of life across various sectors including medical products, pharmaceuticals, agriculture, food, and industry.

The SFDA has proactively adjusted its organisational structure to align with the national strategy. This includes creating specialised departments within sectors such as food, medicine, medical devices, and laboratories.

Additionally, Dr. Al-Jadhey urged stakeholders to actively participate in shaping the future of biotechnology regulation. He emphasised the importance of collaboration in developing new technologies tailored to public health needs in the Kingdom.

Supporting Research and Development

The SFDA supports research, development, and manufacturing within the biotechnology sector. Through joint efforts, Dr. Al-Jadhey stated that Saudi Arabia could establish a thriving biotechnology ecosystem that fosters innovation.

This collaborative approach aims to attract global investments and cement the Kingdom’s position as a global leader in biotechnology.

"Through joint efforts," he stated, "Saudi Arabia could establish a thriving biotechnology ecosystem that fosters innovation."

The National Biotechnology Strategy aims to enhance various sectors by integrating advanced biotechnological solutions. This holistic approach ensures comprehensive improvements across medical products, pharmaceuticals, agriculture, food, and industry.

Dr. Al-Jadhey noted that these efforts are crucial for developing new technologies tailored to public health needs in the Kingdom. The SFDA's proactive adjustments reflect its commitment to aligning with national goals and fostering a supportive environment for biotechnological advancements.

The emphasis on collaboration highlights the importance of joint efforts in achieving these ambitious goals. By working together with stakeholders and experts from various fields, Saudi Arabia aims to create an innovative ecosystem that attracts global investments and solidifies its leadership in biotechnology.

With inputs from SPA